CAJ | 학술논문

目的探讨18 F-FDG PET/CT在T细胞淋巴瘤临床再分期、评价疗效、监测复发及提示预后方面的临床价值.方法回顾性分析34例T细胞淋巴瘤患者的PET/CT显像结果,评价其在临床再分期、评价疗效、监测复发及提示预后方面的价值.结果 34例患者中20例分期Ⅰ～Ⅱ期者治疗后6例分期上调,9例分期下调,5例分期未改变；14例分期Ⅲ～Ⅳ期者治疗后3例分期上调,4例分期下调,7例分期未改变.34例T细胞淋巴瘤患者中12例达完全缓解(CR),11例达部分缓解(PR),2例处于稳定(SD)状态,9例进展(PD).34例患者中有25例至少经6个疗程化疗后行PET/CT检查,疗效较佳组的标准化摄取(SUV)值比疗效不佳组的SUV值小(分别为4.3±3.1和11.2+6.1),差异有统计学意义(P =0.009).8例患者于治疗前后均行PET/CT检查,治疗前后SUV值差异有统计学意义(P=0.000).25例外周T细胞淋巴瘤至少经6个疗程化疗后PET/CT评价疗效较佳组与疗效不佳组的平均生存时间(分别为82.7和39.5个月)差异有统计学意义(P=0.015).结论 T细胞淋巴瘤治疗后行PET/CT检查对于指导临床再分期、评价疗效、监测复发及提示预后有一定意义,有助于临床早期判断疗效及制定个体化治疗方案.
목적 탐토18 F-FDG PET/CT재T세포림파류림상재분기、평개료효、감측복발급제시예후방면적림상개치.방법 회고성분석34례T세포림파류환자적PET/CT현상결과,평개기재림상재분기、평개료효、감측복발급제시예후방면적개치.결과 34례환자중20례분기Ⅰ～Ⅱ기자치료후6례분기상조,9례분기하조,5례분기미개변；14례분기Ⅲ～Ⅳ기자치료후3례분기상조,4례분기하조,7례분기미개변.34례T세포림파류환자중12례체완전완해(CR),11례체부분완해(PR),2례처우은정(SD)상태,9례진전(PD).34례환자중유25례지소경6개료정화료후행PET/CT검사,료효교가조적표준화섭취(SUV)치비료효불가조적SUV치소(분별위4.3±3.1화11.2+6.1),차이유통계학의의(P =0.009).8례환자우치료전후균행PET/CT검사,치료전후SUV치차이유통계학의의(P=0.000).25예외주T세포림파류지소경6개료정화료후PET/CT평개료효교가조여료효불가조적평균생존시간(분별위82.7화39.5개월)차이유통계학의의(P=0.015).결론 T세포림파류치료후행PET/CT검사대우지도림상재분기、평개료효、감측복발급제시예후유일정의의,유조우림상조기판단료효급제정개체화치료방안.
Objective To investigate the usefulness of 18F-FDG PET/CT imaging in restaging,evaluating the treatment outcome,monitoring relapse and predicting prognosis of T-cell lymphoma.Methods Retrospective analysis of PET/CT image results of thirty-four patients with T-cell lymphoma,and to evaluate its clinical significance in restaging,treatment efficiency,relapse monitor and progrosis prediction.Results Clinical restaging among the 20 stage Ⅰ and Ⅱ patients,6 were ascended,9 descended and 5 unchanged.Restaging among the other 14 stage Ⅲ and Ⅳ patients,3 were ascended,4 descended and 7 unchanged.There were 12 patients in complete remission( CR),11 in partial remission( PR),2 in stable disease(SD)and 9 in progressive disease (PD) among all the 34 patients.There is obvious statistical difference of the standardized uptake value(SUV) between the efficacy group and the inefficacy group after treatment of 6 courses at least in 25 patients among all the 34 patients( P =0.009).There is obvious statistical difference of the SUV value before and after treatment in 8 patients among all the 34 patients(P =0.000).There is obvious statistical difference in the survival time between the efficacy group and the inefficacy group after treatment of 6 courses at least in 25 patients among all the 34 patients( P =0.015 ).Conclusions 18F-FDG PET/CT imaging plays an very important role in guiding clinical restaging,evaluating the treatment outcome,monitoring relapse and predicting prognosis of T-cell lymphoma. It is helpful to establish personalized treatment planning.